Business Wire

AMCS Acquires Qv21 Technologies, Strengthening Its Transportation Management Capabilities

Share

Qv21 Technologies’ fleet management and logistics SaaS solutions to support improved waste-to-resource conversion and sustainability for organizations

AMCS, a global leader of sustainability software for foundational industries, announced today its acquisition of Qv21 Technologies, a leading provider of fleet management and logistics SaaS solutions for short-haul, bulk commodity transportation, for an undisclosed amount.

Founded in 2009 in Austin, Texas, Qv21 Technologies enables short-haul and bulk commodity trucking companies of all sizes to increase operational visibility and improve overall efficiency. With their mission of enabling Logistics Without Barriers™, Qv21’s powerful solution, The LogisticsFramework™ (TLF), streamlines business processes from order to invoice. Backed with robust data management, workflow automation, and analytics capabilities, Qv21 ensures organizations are in complete control of their operations while boosting their savings and profit margins.

The innovative fleet management and logistics solutions by Qv21 Technologies, along with its North American footprint and focus on bulk material transportation, are highly complementary to the AMCS Platform, benefiting customers of both organizations. The acquisition empowers AMCS to expand the capabilities of the AMCS Platform, enabling resource-intensive industries to achieve their sustainability goals faster, more efficiently, and profitably.

“Qv21 Technologies has consistently offered innovative solutions built for short-haul, bulk commodity transportation companies, enhancing operational excellence for leading organizations, including those in the waste and recycling sectors,” said Jonathan Currie, CEO, Qv21 Technologies. “Qv21's commitment to 'Logistics Without Barriers' boosts efficiency and profitability for transporters. Beyond the opportunities for business expansion, our partnership with AMCS further strengthens this pursuit of operational excellence for our clients and accelerates our collective vision for greater sustainability.“

This acquisition paves the way for several synergistic opportunities to be realized, specifically aiding organizations in the long-haul transport of bulk commodities that can support a more circular economy vision. Materials that were previously considered waste and destined for landfill sites can now be effectively directed towards reuse or recycling facilities. With Qv21, AMCS can provide organizations with a solution for a more structured, efficient approach to resource utilization and improved waste management, translating to meaningful progress toward their sustainability goals.

“The strategic addition of Qv21 Technologies signifies a crucial advancement for AMCS, reinforcing our position at the forefront of Performance Sustainability,” explained, Jimmy Martin, co-founder and CEO, AMCS. “This partnership provides tremendous opportunities, specifically for companies engaged within bulk material transportation, to reach their sustainability goals faster. The features that Qv21 brings to the table serve to enhance our capabilities at AMCS, strengthening our ability to support our clients' drive towards enhanced resource management, greater efficiency, sustainability, growth, and profitability.”

AMCS’ Performance Sustainability Suite is the operating system for foundational industries that makes sustainability and profitability possible. The suite manages the running of day-to-day operations such as contracts and pricing, logistics and transportation, materials and resources, health and safety, and sustainability intelligence. The AMCS Performance Sustainability Suite drives growth and profitability, optimizes efficiency and safety, powers corporate sustainability initiatives, and prepares businesses for the circular economy and the future. With AMCS, businesses can improve performance and scale more easily, enabling foundational industry professionals to leave the planet in a better way than they found it.

About Qv21 Technologies
Founded in 2009, Qv21 Technologies is an industry-leading SaaS company specializing in Transportation Management Systems for short-haul, bulk commodity transport. Dedicated to building cloud-based tools, Qv21 supports transporters, carriers, and commodity buyers in navigating industry challenges.

Qv21 Technologies’ flagship solution, The LogisticsFramework™ (TLF), increases operational visibility and streamlines business processes, from order to invoice. As a committed technology provider to trucking companies of all sizes, Qv21 makes increasing savings and profit margins achievable, restoring control of operations back to the organization. Learn more at www.qv21.com

About AMCS
At AMCS we are focused on Performance Sustainability – enabling resource-intensive industries to boost sustainability and profitability. Built on decades of experience, our purpose-built software solutions are designed by people who understand your business, providing practical solutions for the resources, waste, recycling, transportation, manufacturing, and utilities industries.

Headquartered in Ireland, and with offices in Europe, the USA, and Australia, AMCS is a global market leader with over 1,300 mission-driven team members. The combined expertise of our team allows AMCS to deliver innovative solutions and extensive insight, helping customers to drive growth and achieve lasting success. As a trusted global partner, we work with 3800 customers in more than 80 countries delivering digital solutions that create meaningful and measurable impact by increasing customer satisfaction, enhancing sustainability, and boosting margins.

At AMCS, we're ready to innovate with you - deploying our experts, processes, and technology to drive your business forward and prepare you for success in a more sustainable, net zero carbon future. Learn more at: www.amcsgroup.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904279752/en/

Contacts

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye